Peloton Wealth Strategists Sells 1,800 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Peloton Wealth Strategists trimmed its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 3.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 44,830 shares of the biotechnology company’s stock after selling 1,800 shares during the quarter. Peloton Wealth Strategists’ holdings in Exelixis were worth $1,493,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. MassMutual Private Wealth & Trust FSB boosted its position in Exelixis by 18.1% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 290 shares in the last quarter. Covestor Ltd boosted its position in Exelixis by 5.7% during the 3rd quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 341 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its position in Exelixis by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock valued at $1,937,000 after acquiring an additional 354 shares in the last quarter. Principal Securities Inc. boosted its position in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 373 shares in the last quarter. Finally, V Square Quantitative Management LLC boosted its position in Exelixis by 37.3% during the 4th quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 425 shares in the last quarter. 85.27% of the stock is owned by institutional investors.

Exelixis Trading Up 0.3 %

NASDAQ:EXEL opened at $37.65 on Friday. Exelixis, Inc. has a 12 month low of $20.14 and a 12 month high of $38.43. The company has a market cap of $10.54 billion, a PE ratio of 21.27, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53. The company has a 50 day simple moving average of $34.42 and a two-hundred day simple moving average of $31.54.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on EXEL shares. Oppenheimer lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $41.00 to $33.00 in a report on Friday, January 24th. Truist Financial lifted their target price on shares of Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a report on Monday, January 27th. Piper Sandler lifted their target price on shares of Exelixis from $37.00 to $38.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. JMP Securities reiterated a “market outperform” rating and set a $41.00 target price on shares of Exelixis in a report on Thursday, January 23rd. Finally, Morgan Stanley upgraded shares of Exelixis from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $30.00 to $40.00 in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $37.24.

Insiders Place Their Bets

In other news, Director Bob Oliver sold 18,647 shares of the company’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total value of $694,600.75. Following the completion of the sale, the director now directly owns 33,514 shares in the company, valued at $1,248,396.50. This represents a 35.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Christopher J. Senner sold 29,314 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.14, for a total value of $1,059,407.96. Following the completion of the sale, the chief financial officer now owns 779,607 shares of the company’s stock, valued at $28,174,996.98. This trade represents a 3.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 112,807 shares of company stock valued at $4,126,373. Company insiders own 2.85% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.